Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.48 |
| ▸ | CTSS | P25774 | 8/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386088 | 1.00 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL10161266 | 1.00 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL21724289 | 0.93 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL21724288 | 0.93 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL33528827 | 0.90 | CTSK (0.49) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL33528044 | 0.90 | CTSK (0.49) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL30064534 | 0.89 | CTSK (0.45) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL30407324 | 0.85 | REN (0.44) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL863895 | 0.85 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL3773280 | 0.85 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2224927-B1 | PTERIN ANALOG FOR TREATING BH4 RESPONSIVE CONDITION | BIOMARIN PHARM INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8324210-B2 | Pterin analogs | BIOMARIN PHARMACEUTICAL, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120022072-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2224927-A1 | PTERIN ANALOG FOR TREATING BH4 RESPONSIVE CONDITION | BioMarin Pharmaceutical Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100093742-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100016328-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2114944-A2 | TETRAHYDROBIOPTERIN PRODRUGS | BioMarin Pharmaceutical Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7601717-B2 | Pterin analogs | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2009088530-A1 | PTERIN ANALOG FOR TREATING BH4 RESPONSIVE CONDITION | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176790-A1 | For treating conditions responsive to tetrahydrobiopterin therapies | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2008089008-A2 | TETRAHYDROBIOPTERIN PRODRUGS | BIOMARIN PHARMACEUTICAL INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093742-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | CTSK 2446/4885CTSS 2910/4885CTSL 1359/4885 |
| US-20100016328-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | CTSK 2446/4885CTSS 2910/4885CTSL 1359/4885 |
| US-20120022072-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | CTSK 2446/4885CTSS 2910/4885CTSL 1359/4885 |
| US-20090176790-A1 | For treating conditions responsive to tetrahydrobiopterin therapies | TPMT, LTB4R2, BDKRB2 | CTSK 1852/4885CTSS 2028/4885CTSL 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.